610 related articles for article (PubMed ID: 16077991)
1. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
Bhuvarahamurthy V; Schroeder J; Kristiansen G; Roigas J; Denkert C; Johannsen M; Lein M; Loening SA; Schnorr D; Jung K; Staack A
Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
[TBL] [Abstract][Full Text] [Related]
2. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
3. Modulation of urokinase and urokinase receptor gene expression in human renal cell carcinoma.
Wagner SN; Atkinson MJ; Thanner S; Wagner C; Schmitt M; Wilhelm O; Rotter M; Höfler H
Am J Pathol; 1995 Jul; 147(1):183-92. PubMed ID: 7604879
[TBL] [Abstract][Full Text] [Related]
4. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
5. Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells.
Hagiwara H; Sato H; Shirai S; Kobayashi S; Fukumoto K; Ishida T; Seki T; Ariga T; Yano T
Life Sci; 2006 Apr; 78(19):2249-54. PubMed ID: 16289236
[TBL] [Abstract][Full Text] [Related]
6. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
Zhou Q; Liang LJ; Peng BG; Zhen YY
Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
[TBL] [Abstract][Full Text] [Related]
7. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
8. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
9. [Association of uPA and uPAR expression with invasive behaviors of urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Ai Zheng; 2004 Jun; 23(6):704-6. PubMed ID: 15191676
[TBL] [Abstract][Full Text] [Related]
10. [The expression of urokinase-type plasminogen activator and its receptor in urinary transitional cell carcinoma].
Li YJ; Zheng BZ; Zhou ZL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):57-9. PubMed ID: 14981816
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
13. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B
Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
[TBL] [Abstract][Full Text] [Related]
14. Significant down-regulation of the plasminogen activator inhibitor 1 mRNA in pancreatic cancer.
Warnecke-Eberz U; Prenzel KL; Baldus SE; Metzger R; Dienes HP; Bollschweiler E; Hoelscher AH; Schneider PM
Pancreas; 2008 Mar; 36(2):173-7. PubMed ID: 18376309
[TBL] [Abstract][Full Text] [Related]
15. [Expression of urokinase-type plasminogen activator and its receptor protein in synovial tissues from osteoarthritis].
Wang WC; Wang Y; Sun CJ
Hunan Yi Ke Da Xue Xue Bao; 2001 Jun; 26(3):257-60. PubMed ID: 12536699
[TBL] [Abstract][Full Text] [Related]
16. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
[TBL] [Abstract][Full Text] [Related]
17. Posttranscriptional regulation of urokinase receptor expression by heterogeneous nuclear ribonuclear protein C.
Velusamy T; Shetty P; Bhandary YP; Liu MC; Shetty S
Biochemistry; 2008 Jun; 47(24):6508-17. PubMed ID: 18494499
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
19. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
20. Expression and function of the urokinase type plasminogen activator during mouse hemochorial placental development.
Teesalu T; Blasi F; Talarico D
Dev Dyn; 1998 Sep; 213(1):27-38. PubMed ID: 9733098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]